Internist and Nephrologist specialized in GN and Hypertension.Assistant Professor at @kauedu_sa and part time Consultant at @HMG
Jeddah
Joined January 2011
- Tweets17.9K
- Following586
- Followers1.3K
- Likes3.3K
Naif Alghamdi retweeted
CONGRESS | #ACR26 | POSTER
Richard Furie presents results from a pooled analysis of the phase III TULIP-1 (NCT02446912), TULIP-2 (NCT02446899), and TULIP-SC (NCT04877691) trials evaluating organ system improvements with anifrolumab (300mg IV Q4W or 120mg SC QW; n = 544) vs placebo (n = 549) in patients with SLE.
At Week 52, a greater proportion of patients treated with anifrolumab vs placebo demonstrated improvements in the SLEDAI-2K mucocutaneous, musculoskeletal, hematological, and immunology systems; treatment differences were observed as early as Weeks 4–8 in some systems. Similarly, higher proportions of patients with anifrolumab vs placebo showed improvement in BILAG-2004 (classified as ≥1 BILAG-2004 score shift from baseline to Week 52) in the musculoskeletal, mucocutaneous, cardiorespiratory, and renal domains.
Follow our live feed for more updates: bit.ly/4iUYXQy
Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence.
#Lupus #Rheumatology #RheumTwitter #MedEd #MedNews #MedicalCongress @NorthwellHealth
Naif Alghamdi retweeted
#Hyperaldosteronism Remission after Extended #Aldosterone Synthase Inhibition
14-patient cohort: Improvements persisted up to 2 years after treatment cessation. BP ⬇️ by approximately 25 mm Hg, with 23% estimated clinical success.
📌 Aldosterone-to-renin ratio: 210.0 → 1.29 at 1–2 years (n=9)—a 99.2% reduction (95% CI, 98.2–99.6).
nejm.org/doi/full/10.1056/NE…
#ScientificSessions26 #AHA26 @AHAScience
Naif Alghamdi retweeted
Presented at #ScientificSessions26:
In patients with type 2 diabetes and high cardiovascular risk, a systolic blood-pressure target below 120 mm Hg did not result in fewer major cardiovascular events than a target below 140 mm Hg. Full OPTIMAL-DIABETES trial results: nej.md/3UZYKCy
@AHAScience
ALT A graph from the Original Article "Intensive Blood-Pressure Lowering in Patients with Type 2 Diabetes.” The trial name, OPTIMAL-DIABETES, is in parentheses after the title. The graph shows Kaplan–Meier curves for the primary outcome. The trial results are being presented at the American Heart Association Scientific Sessions 2026. The logo of the New England Journal of Medicine is at the bottom.
Naif Alghamdi retweeted
Antihypertensive pharmacotherapy in chronic kidney disease: integrating estimated glomerular filtration rate-based cutoffs, mechanistic insights, and emerging therapeutic pathways
academic.oup.com/ajh/advance…
#WeekendReads
Naif Alghamdi retweeted
New for 2027: the GlomCon Transplant Scholars Program.
A 10-Month online program dedicated to advancing education in kidney transplantation: From candidate evaluation to post-transplant management, including pathology, protocols, complications, and living donor assessment.
Directed by Nay Seif, MD, MS, and Anshul Bhalla, MD. Built for fellows and practicing nephrologists.
Applications open November 9, 2026.
Learn more at glomcon.org
#Nephrology #KidneyTransplant #NephTwitter #GlomCon
Naif Alghamdi retweeted
The Kidney Pathology Certificate Program returns for its 2027 cohort.
Twelve months, six modules, from biopsy basics to allograft pathology: Live case webinars led by renal pathologists and nephrologists, pre-recorded lectures, and a certificate upon completion of program.
Directed by Vanesa Bijol, MD and Ibrahim Batal, MD.
Applications open on October 26, 2026.
Learn more at glomcon.org
#RenalPathology #Nephrology #Nephropathology #GlomCon
Naif Alghamdi retweeted
Now off to April/BAFF targeting therapies in IgAN by Dr. Ali Mehdi @CleClinicKidney @GlomCon @glomconarabia
Naif Alghamdi retweeted
A brilliant @glomconarabia session on IgA Nephropathy by the amazing Dr. Ali Mehdi @CleClinicKidney @GlomCon
Naif Alghamdi retweeted
We are excited to host another session in the GlomCon Arabia Seminar Series on Friday, October 9th, 2026.
This session will feature an expert presentation by Dr. Ali Mehdi MD, MEd, FACP, FASN, with Dr. Naif Ali A A Alghamdi, MBBS, FASN, CHS (AHSCP) as moderator titled “IgA Nephropathy: Where We Are and Where We Are Going.”
Meeting details:
glomcon.zoom.us
Zoom ID: 884 4208 1901
Passcode: 100499
Find event details at glomcon.org/arabia-glomcon
We invite you to join us for this informative session and connect with colleagues from around the world!
#GlomCon #GlomConArabia #IgANephropathy #Nephrology #KidneyHealth #KidneyEducation #NephrologyEducation #MedicalCommunity #GlobalMedicine
Naif Alghamdi retweeted
We are excited to host another session in the GlomCon Arabia Seminar Series tomorrow Friday, October 9, 2026
This session will feature an expert presentation by Dr. Ali Mehdi “IgA Nephropathy: Where We Are and Where We Are Going”
Meeting details:
glomcon.zoom.us
Meeting ID: 884 4208 1901
Passcode: 100499
@GlomCon @glomconarabia #NephrologyEducation #MedicalCommunity #GlobalMedicine @CleClinicKidney
Naif Alghamdi retweeted
DIALIZE-Outcomes data showed sodium zirconium cyclosilicate did not increase edema, heart failure, hypertension, or weight gain versus placebo in hemodialysis patients, according to study in #ASNKidney360. kidney.pub/KID1330
Naif Alghamdi retweeted
Causes of Infection-Related Glomerulonephritis
From Dr. Hala Kassouf's lecture @glomconarabia
Naif Alghamdi retweeted
Join us today for an expert presentation by Dr. Hala Kfoury Kassouf titled “Infection-related Kidney Injury: Mechanisms, Implications, and Pathological Insights”
Meeting details:
glomcon.zoom.us
Meeting ID: 884 4208 1901
Passcode: 100499
lnkd.in/d5Ta7sQg
Naif Alghamdi retweeted
Dr S Almaani reviews the data on PLEX and provides his perspective with AAV #WUSTLneph @ting2li
Naif Alghamdi retweeted
Benefits of SGLT2i exceed serious harms regardless of polypharmacy status, with greatest absolute effects in patients with higher medication burden
New CREDENCE analysis from @emilykyeung in @NDTsocial doi.org/10.1093/ndt/gfag203
Naif Alghamdi retweeted
Now open access in @NDTsocial @fervenzaf
Protocol biopsy in class III/IV lupus nephritis: barking up the wrong tree!
🧐Evaluating activity in LN is not done by performing protocol kidney biopsies, but by looking at the serological activity.
▶️academic.oup.com/ndt/article…
Naif Alghamdi retweeted
REVIEW: Current and Novel Biomarkers for Diagnosis and Subtyping of Primary Aldosteronism
ahajrnls.org/4wPVPcl
Naif Alghamdi retweeted
7/ The essential HTN profile runs the other way: older, male, established HTN with risk factors, milder AKI, milder TMA, rare thrombi on biopsy. These are profiles, not validated criteria, and plenty of patients sit in between.
Naif Alghamdi retweeted
6/ Features favoring complement-mediated TMA over BP alone (Praga et al, KI 2026): younger, female, no prior HTN or risk factors for it, severe AKI, severe anemia and thrombocytopenia, low C3, family history, glomerular and arteriolar thrombi. @Kidney_Int
